QQQ   332.34 (+0.59%)
AAPL   173.11 (+0.59%)
MSFT   293.08 (+0.40%)
META   180.75 (+0.14%)
GOOGL   122.10 (+0.35%)
AMZN   143.02 (-0.37%)
TSLA   932.90 (+3.65%)
NVDA   188.65 (+0.83%)
NIO   21.31 (+0.95%)
BABA   94.06 (-0.75%)
AMD   100.70 (-0.13%)
MU   64.38 (-1.01%)
T   18.41 (+0.77%)
CGC   3.81 (+15.45%)
GE   79.72 (-0.26%)
F   16.35 (+1.05%)
DIS   124.35 (+2.29%)
AMC   23.68 (-3.11%)
PYPL   101.27 (+0.17%)
PFE   49.47 (-1.28%)
NFLX   248.72 (-0.23%)
QQQ   332.34 (+0.59%)
AAPL   173.11 (+0.59%)
MSFT   293.08 (+0.40%)
META   180.75 (+0.14%)
GOOGL   122.10 (+0.35%)
AMZN   143.02 (-0.37%)
TSLA   932.90 (+3.65%)
NVDA   188.65 (+0.83%)
NIO   21.31 (+0.95%)
BABA   94.06 (-0.75%)
AMD   100.70 (-0.13%)
MU   64.38 (-1.01%)
T   18.41 (+0.77%)
CGC   3.81 (+15.45%)
GE   79.72 (-0.26%)
F   16.35 (+1.05%)
DIS   124.35 (+2.29%)
AMC   23.68 (-3.11%)
PYPL   101.27 (+0.17%)
PFE   49.47 (-1.28%)
NFLX   248.72 (-0.23%)
QQQ   332.34 (+0.59%)
AAPL   173.11 (+0.59%)
MSFT   293.08 (+0.40%)
META   180.75 (+0.14%)
GOOGL   122.10 (+0.35%)
AMZN   143.02 (-0.37%)
TSLA   932.90 (+3.65%)
NVDA   188.65 (+0.83%)
NIO   21.31 (+0.95%)
BABA   94.06 (-0.75%)
AMD   100.70 (-0.13%)
MU   64.38 (-1.01%)
T   18.41 (+0.77%)
CGC   3.81 (+15.45%)
GE   79.72 (-0.26%)
F   16.35 (+1.05%)
DIS   124.35 (+2.29%)
AMC   23.68 (-3.11%)
PYPL   101.27 (+0.17%)
PFE   49.47 (-1.28%)
NFLX   248.72 (-0.23%)
QQQ   332.34 (+0.59%)
AAPL   173.11 (+0.59%)
MSFT   293.08 (+0.40%)
META   180.75 (+0.14%)
GOOGL   122.10 (+0.35%)
AMZN   143.02 (-0.37%)
TSLA   932.90 (+3.65%)
NVDA   188.65 (+0.83%)
NIO   21.31 (+0.95%)
BABA   94.06 (-0.75%)
AMD   100.70 (-0.13%)
MU   64.38 (-1.01%)
T   18.41 (+0.77%)
CGC   3.81 (+15.45%)
GE   79.72 (-0.26%)
F   16.35 (+1.05%)
DIS   124.35 (+2.29%)
AMC   23.68 (-3.11%)
PYPL   101.27 (+0.17%)
PFE   49.47 (-1.28%)
NFLX   248.72 (-0.23%)
NASDAQ:PACB

Pacific Biosciences of California - PACB Stock Forecast, Price & News

$8.31
-0.48 (-5.46%)
(As of 08/15/2022 01:52 PM ET)
Add
Compare
Today's Range
$8.26
$9.24
50-Day Range
$3.93
$8.79
52-Week Range
$3.85
$32.55
Volume
330,122 shs
Average Volume
6.97 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.40

Pacific Biosciences of California MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
103.0% Upside
$17.40 Price Target
Short Interest
Healthy
15.73% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.05mentions of Pacific Biosciences of California in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.39) to ($1.25) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

630th out of 1,128 stocks

Analytical Instruments Industry

14th out of 31 stocks

PACB stock logo

About Pacific Biosciences of California (NASDAQ:PACB) Stock

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Cowen reduced their target price on shares of Pacific Biosciences of California to $8.00 in a research note on Tuesday, August 9th. Canaccord Genuity Group cut their price target on shares of Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, August 5th. Cantor Fitzgerald cut their price target on shares of Pacific Biosciences of California from $23.00 to $19.00 in a research note on Thursday, May 5th. Finally, Piper Sandler dropped their price objective on shares of Pacific Biosciences of California from $13.00 to $6.00 and set a "na" rating for the company in a report on Sunday, May 15th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Pacific Biosciences of California presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.00.

Pacific Biosciences of California Price Performance

Shares of Pacific Biosciences of California stock traded up $0.85 during midday trading on Friday, reaching $8.79. The company had a trading volume of 22,342,151 shares, compared to its average volume of 11,308,990. The company has a debt-to-equity ratio of 1.31, a quick ratio of 16.38 and a current ratio of 11.50. The stock has a fifty day simple moving average of $5.01 and a 200 day simple moving average of $7.40. Pacific Biosciences of California has a 1-year low of $3.85 and a 1-year high of $32.55.

Pacific Biosciences of California (NASDAQ:PACB - Get Rating) last issued its quarterly earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. Pacific Biosciences of California had a negative net margin of 147.39% and a negative return on equity of 35.76%. During the same period last year, the company earned ($0.21) earnings per share. Equities research analysts expect that Pacific Biosciences of California will post -1.39 EPS for the current year.

Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Stock News Headlines

Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
PacBio Announces Second Quarter 2022 Financial Results
Pacific Biosciences: Lacks Forward Upside Capture
See More Headlines
Receive PACB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter.

PACB Company Calendar

Last Earnings
8/03/2022
Today
8/15/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:PACB
CUSIP
69404D10
Employees
728
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$17.40
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+109.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-181,220,000.00
Net Margins
-147.39%
Pretax Margin
-214.50%

Debt

Sales & Book Value

Annual Sales
$130.51 million
Book Value
$3.59 per share

Miscellaneous

Free Float
221,693,000
Market Cap
$1.87 billion
Optionable
Optionable
Beta
1.44

Social Links


Key Executives

  • Mr. Christian O. Henry M.B.A. (Age 54)
    Pres, CEO & Director
    Comp: $1.42M
  • Ms. Susan G. Kim (Age 46)
    Chief Financial Officer
    Comp: $671.49k
  • Mr. Mark Van Oene (Age 49)
    Chief Operating Officer
    Comp: $1.12M
  • Dr. Denis Zaccarin Ph.D. (Age 56)
    Sr. VP of Product Devel.
    Comp: $510.77k
  • Dr. Stephen Turner (Age 54)
    Co-Founder & CTO
  • Ms. Michele Farmer CPA (Age 42)
    VP & Chief Accounting Officer
  • Dr. Jonas Korlach Ph.D.
    Chief Scientific Officer
  • Trevin Rard
    Head of Investor Relations
  • Dr. Brett Atkins J.D.
    Ph.D., Gen. Counsel & Corp. Sec.
  • Ms. Kathleen Lynch J.D.
    Head of Global Gov. Affairs & Corp. Communications













PACB Stock - Frequently Asked Questions

Should I buy or sell Pacific Biosciences of California stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PACB shares.
View PACB analyst ratings
or view top-rated stocks.

What is Pacific Biosciences of California's stock price forecast for 2022?

3 brokerages have issued twelve-month target prices for Pacific Biosciences of California's shares. Their PACB share price forecasts range from $6.00 to $40.00. On average, they anticipate the company's stock price to reach $17.40 in the next year. This suggests a possible upside of 98.0% from the stock's current price.
View analysts price targets for PACB
or view top-rated stocks among Wall Street analysts.

How have PACB shares performed in 2022?

Pacific Biosciences of California's stock was trading at $20.46 on January 1st, 2022. Since then, PACB stock has decreased by 57.0% and is now trading at $8.79.
View the best growth stocks for 2022 here
.

When is Pacific Biosciences of California's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PACB earnings forecast
.

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings data on Wednesday, August, 3rd. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 35.76% and a negative net margin of 147.39%. During the same period in the prior year, the firm posted ($0.21) EPS.

What guidance has Pacific Biosciences of California issued on next quarter's earnings?

Pacific Biosciences of California updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $138.00 million-$145.00 million, compared to the consensus revenue estimate of $161.95 million.

What is Christian Henry's approval rating as Pacific Biosciences of California's CEO?

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacific Biosciences of California own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (6.39%), Nikko Asset Management Americas Inc. (6.39%), Northern Trust Corp (0.94%), FMR LLC (0.54%), Mirae Asset Global Investments Co. Ltd. (0.44%) and JPMorgan Chase & Co. (0.35%). Insiders that own company stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends
.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $8.79.

How much money does Pacific Biosciences of California make?

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $1.98 billion and generates $130.51 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Pacific Biosciences of California have?

The company employs 728 workers across the globe.

Does Pacific Biosciences of California have any subsidiaries?

The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.
Read More

When was Pacific Biosciences of California founded?

Pacific Biosciences of California was founded in 2004.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.

This page (NASDAQ:PACB) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.